Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 9/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15758800 | 0.88 | HPGD (0.35) | F10PGR | |
| SCHEMBL15764955 | 0.85 | CHRM2 (0.33) | F10PGR | |
| SCHEMBL17974432 | 0.82 | CHRM2 (0.34) | PGR | |
| SCHEMBL15765227 | 0.81 | NAMPT (0.38) | DRD2RORCACACBPGRACKR3 | |
| SCHEMBL17974431 | 0.81 | AQP1 (0.35) | PGR | |
| SCHEMBL15765047 | 0.81 | PGR (0.37) | F10DRD2RORCACACBACACA | |
| Hydrochloric Acid SCHEMBL15758122 | 0.80 | AQP1 (0.34) | — | |
| SCHEMBL15764957 | 0.78 | RORC (0.40) | DRD2RORCACACBACACANAMPT | |
| SCHEMBL17961398 | 0.77 | MAPT (0.33) | F10NAMPT | |
| SCHEMBL15764956 | 0.77 | MAPT (0.33) | F10NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | Karyopharm Therapeutics Inc. | 2016-08-04 | — | — | US | disclosed |
| WO-2014085607-A1 | SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. (US) | 2014-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221994-A1 | Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof | BCL6, MALT1, BCL3 | F10 1099/4885DRD2 2012/4885RORC 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.